Modeling patients’ time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants

BACKGROUND: Anticoagulation therapy is used for atrial fibrillation (AF) patients for reducing the risk of cardioembolic complications such as stroke. The previously recommended anticoagulant, warfarin, has a narrow therapeutic window, and it requires regular laboratory monitoring, unlike direct ora...

Descripción completa

Detalles Bibliográficos
Autores principales: Leminen, Aapeli, Pyykönen, Mikko, Tynkkynen, Juho, Tykkyläinen, Markku, Laatikainen, Tiina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882009/
https://www.ncbi.nlm.nih.gov/pubmed/31775847
http://dx.doi.org/10.1186/s12913-019-4711-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882009/
https://www.ncbi.nlm.nih.gov/pubmed/31775847
http://dx.doi.org/10.1186/s12913-019-4711-z

Ejemplares similares